Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

102.09 -1.49 (-1.44%)
Official Closing Price Updated: 7:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,053,724
Open 102.86
Bid (Size) 95.00 (1)
Ask (Size) 105.00 (1)
Prev. Close 103.58
Today's Range 102.05 - 102.92
52wk Range 74.09 - 105.61
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Preventable Vaccines Market May See a Big Move : AstraZeneca, GlaxoSmithKline, Merck
Stay up-to-date with Preventable Vaccines Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Bloomberg 
Via Benzinga

Performance

YTD
+10.71%
+10.71%
1 Month
-0.49%
-0.49%
3 Month
+1.54%
+1.54%
6 Month
+23.73%
+23.73%
1 Year
+31.66%
+31.66%

More News

Read More
Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact
Via Benzinga
2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Price Over Earnings Overview: Novartis
Via Benzinga
Peering Into Novartis's Recent Short Interest
Via Benzinga
AMC Stock Alert: Adam Aron Teases New Chocolate, Wine Brands for AMC
Via InvestorPlace
Why Is Canopy Growth (CGC) Stock Up 14% Today?
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
NVS Stock Alert: Novartis Shareholders Approve Sandoz Spinoff
Via InvestorPlace
Instacart Mulls IPO Price Hike After Arm's Stellar Debut, UAW Launches Historic Simultaneous Strike, China Sanctions Lockheed Martin & Northrop Grumman Concerning Taiwan Arms Sales: Today's Top Stories
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off
Via Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories
Via Benzinga
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
Via Benzinga
AI 2.0 is Here: How to Invest in a Generational Opportunity
Via MarketBeat
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence Supply Chain
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Via The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Via The Motley Fool
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Via MarketBeat
Topics Economy
Exposures Interest Rates
Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet
Via Benzinga
Sex Hormones Market to See Huge Growth by 2028 : Novartis, Sanofi, AstraZeneca, Merck
Via SBWire
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Via The Motley Fool
Transdermal Drug Patches Market to See Huge Growth : Novartis, Mylan, Accrux
Via SBWire
Exposures COVID-19
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
Via Benzinga
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.